Liver Nodule Found in 35-Year-Old Woman

Poll

A 35-year-old woman was found to have a 4 cm nodule in the liver. After a biopsy is performed, what is your diagnosis?

A 35-year-old woman was found to have a 4 cm nodule in the liver. According to the histology slide below, what is your diagnosis?

What is your diagnosis?

A. Hepatocellular carcinoma
B. Hepatitis C
C. Metastatic adenocarcinoma
D. Focal nodular hyperplasia

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Related Content
Results from the phase 3 MATTERHORN trial support the FDA’s designations for durvalumab in gastric/gastroesophageal junction cancers.

Durvalumab Earns Priority Review, Breakthrough Status in Gastric Cancer

Roman Fabbricatore
August 21st 2025
Article
Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

Geoffrey Y. Ku, MD
August 21st 2025
Podcast
Results from the phase 1a/b trial evaluating ADRX-0405 in various solid tumors, including gastric cancer, are expected to come in late 2025.

FDA Grants Orphan Drug Designation to ADRX-0405 for Gastric Cancer

Tim Cortese
August 21st 2025
Article
Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.

Bemarituzumab Regimen Improves Survival in FGFR2b+ Gastric/GEJ Cancer

Russ Conroy
August 21st 2025
Article
Subgroup analyses from the phase 3 CheckMate 649 and KEYNOTE-859 clinical trials showed little OS difference between investigational and chemotherapy arms.

FDA Limits Pembrolizumab/Nivolumab in PD-L1–Low Gastric Cancer Indications

Roman Fabbricatore
August 21st 2025
Article
Phase 2 data may support nivolumab plus low-dose ipilimumab as a promising option in patients with microsatellite instability–high gastric cancer.

Frontline Nivolumab Combo Shows Enduring Activity in MSI-H Gastric Cancer

Russ Conroy
August 21st 2025
Article